Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma
Name
c9nr06512a.pdf
Description
Published version
Size
3.67 MB
Format
Adobe PDF
Checksum (MD5)
97a0770b170955c80d5be9efec64962b
Author(s)
Nguyen, Hung V. -T.
Johnson, Jeremiah A.
Date Issued
September 2019
Journal
Nanoscale
Publisher
Royal Society of Chemistry (RSC)
Citation
Detappe, Alexandre, et al., "Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma." Nanoscale 11, 43 (Sept. 2019): no. 20485 doi 10.1039/c9nr06512a ©2019 Author(s)
Version
Final published version
Abstract
Monitoring malignant progression and disease recurrence post-therapy are central challenges to improving the outcomes of patients with multiple myeloma (MM). Whereas current detection methods that rely upon bone marrow examination allow for precise monitoring of minimal residual disease and can help to elucidate clonal evolution, they do not take into account the spatial heterogeneity of the tumor microenvironment. As such, they are uninformative as to the localization of malignant plasma cells and may lead to false negative results. With respect to the latter challenge, clinically-available imaging agents are neither sufficiently sensitive nor specific enough to detect minute plasma cell populations. Here, we sought to explore methods by which to improve detection of MM cells within their natural bone marrow environment, using whole-animal magnetic resonance imaging to longitudinally monitor early-stage disease as well as to enhance tumor detection after systemic therapy. We conducted a proof-of-concept study to demonstrate that ultra-small (<5 nm) gadolinium-containing nanoparticles bound to full-length antibodies against the B-cell maturation antigen (BCMA) exhibit rapid tumor uptake followed by renal clearance, improving the signal-to-noise ratio for MM detection beyond levels that are currently afforded by other FDA-approved clinical imaging modalities. We anticipate that when combined with bone marrow or blood biopsy, such imaging constructs could help to augment the effective management of patients with MM. ©2019
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Creative Commons Attribution Noncommercial 3.0 unported license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1039/c9nr06512a
